Hub : Traits :

Alcohol intake frequency.

1277 significantly associated models · 192 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	752566	1620860	1	1	6.6e-08	1.4e-07	6.3e-02	88	RP11-54O7.17
2	2	23453834	25040082	4	2	8.0e-10	2.3e-10	3.2e-01	98	FKBP1B UBXN2A
3	2	26592429	29260106	23	1	2.9e-41	7.6e-40	1.0e+00	100	FNDC4
4	2	44448632	45864710	1	1	1.2e-10	4.9e-10	1.0e+00	100	RP11-89K21.1
5	3	37804853	39280382	2	1	1.9e-07	1.4e-07	1.0e+00	100	ACVR2B
6	3	48757291	50833360	12	2	4.5e-12	2.2e-10	3.6e-01	98	MST1 RBM6
7	3	70757099	71880670	1	1	3.5e-08	4.1e-12	4.5e-06	56	FOXP1
8	3	84317575	86808226	1	1	2.6e-08	2.4e-09	3.3e-03	76	CADM2
9	3	183720576	184256798	1	1	1.5e-07	9.8e-07	6.4e-01	99	ECE2
10	4	2389800	3943984	2	1	1.5e-09	8.6e-11	5.2e-04	71	C4orf44
11	4	38491835	40339574	9	3	1.4e-24	1.8e-32	3.9e-06	85	KLB LIAS RFC1
12	4	99528449	100942337	3	3	1.1e-18	5.0e-46	2.0e-44	4	ADH1B ADH1C
13	5	87006055	88429077	3	1	1.2e-14	1.7e-13	8.5e-01	100	CTC-498M16.2
14	5	131969874	132444509	1	1	1.5e-07	2.6e-07	2.7e-01	96	LEAP2
15	7	44170585	45583220	1	1	6.1e-08	4.9e-08	1.9e-01	94	H2AFV
16	7	72674074	74494207	3	2	1.5e-10	5.5e-07	1.9e-01	93	MLXIPL STAG3L2
17	7	99397218	100746658	1	1	2.4e-07	4.4e-06	1.0e+00	100	NYAP1
18	7	141478308	141994859	1	1	2.9e-08	7.9e-10	3.7e-03	78	MGAM
19	8	142629143	144179460	1	1	2.0e-07	5.9e-09	2.7e-08	9	TSNARE1
20	11	46622392	48485877	11	1	3.1e-13	1.8e-12	3.6e-01	98	C1QTNF4
21	11	64333296	65770658	1	1	6.4e-09	2.0e-08	2.1e-01	95	POLA2
22	12	53926889	55370164	2	1	3.3e-15	1.1e-16	7.8e-03	90	CBX5
23	12	123502044	124005129	1	1	5.2e-08	1.1e-06	7.7e-01	100	CDK2AP1
24	13	49186783	50706551	1	1	3.2e-08	9.0e-09	9.6e-05	54	CAB39L
25	15	77023336	78474476	1	1	6.3e-08	2.7e-07	1.4e-01	92	HMG20A
26	16	27412414	31833122	58	3	3.3e-24	1.9e-21	1.3e-01	97	C16orf93 DOC2A SULT1A2
27	16	68681792	70725815	2	2	3.5e-09	2.2e-07	4.0e-02	84	PDXDC2P TMED6
28	16	71227328	72800567	2	1	5.3e-08	7.6e-07	1.2e-01	90	TXNL4B
29	17	7359757	7856438	1	1	2.9e-07	3.9e-07	4.1e-05	35	EFNB3
30	17	17400972	18923818	10	1	3.7e-10	8.1e-10	1.0e+00	100	LLGL1
31	17	40120771	41510850	1	1	8.4e-09	6.1e-08	1.8e-01	94	TUBG2
32	17	42774693	45796313	18	1	6.9e-12	1.3e-10	7.8e-01	100	LRRC37A
33	17	56950920	58383168	1	1	9.9e-08	1.5e-07	1.1e-01	91	DHX40
34	18	20082830	21863589	3	1	1.8e-19	7.3e-17	9.4e-01	100	NPC1
35	18	52209411	54028036	1	1	1.2e-08	1.3e-08	7.8e-02	90	TCF4
36	19	48464978	49935001	6	1	7.2e-11	1.2e-10	2.5e-01	97	RASIP1
37	20	34828459	36277359	1	1	1.0e-07	1.8e-09	4.1e-04	66	SAMHD1

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Bipolar Disorder (2018)	1.8	1	0	0.0	0.00	1.0e+00	FNDC4
Bipolar Disorder or Schizophrenia	1.5	2	1	2.2	0.00	1.0e+00	CDK2AP1 RASIP1
Depressed Affect (Nagel 2018)	2.9	4	3	6.7	0.64	3.6e-01	C1QTNF4 LRRC37A RBM6 TCF4
Intelligence (Savage-Jansen 2018)	3.7	6	5	11.1	-1.00	4.1e-06	CDK2AP1 FOXP1 MST1 RBM6 SULT1A2 UBXN2A
Neuroticism (Nagel 2018)	2.9	5	3	6.7	0.51	3.9e-01	C1QTNF4 CADM2 CTC-498M16.2 LRRC37A TCF4
Schizophrenia (2018)	1.3	1	0	0.0	0.00	1.0e+00	CDK2AP1
Worry (Nagel 2018)	3.0	5	4	8.9	0.17	7.9e-01	C16orf93 C1QTNF4 CADM2 CTC-498M16.2 LRRC37A
Alzheimer’s Disease (including proxy)	1.8	1	1	2.2	0.00	1.0e+00	C16orf93
Crohns Disease (2017)	3.6	4	4	8.9	0.58	4.2e-01	FNDC4 MST1 RASIP1 SULT1A2
Irritable Bowel Disease (IBD)	3.1	4	3	6.7	0.62	3.8e-01	FNDC4 MST1 RBM6 SULT1A2
Ulcerative Colitis (UC)	1.7	2	1	2.2	0.00	1.0e+00	MST1 SULT1A2
Major Depression (MDD)	1.7	1	0	0.0	0.00	1.0e+00	TCF4
Verbal and Numeric Reasoning (VNR)	3.3	5	4	8.9	-0.99	1.1e-03	FOXP1 MST1 RBM6 SULT1A2 UBXN2A
Breast Cancer	1.5	1	0	0.0	0.00	1.0e+00	LRRC37A
Ovarian Cancer	1.6	1	1	2.2	0.00	1.0e+00	LRRC37A
Age at First Birth	2.4	2	1	2.2	0.00	1.0e+00	MST1 RBM6
Body Mass Index (BMI) (2010)	3.0	2	2	4.4	0.00	1.0e+00	C1QTNF4 SULT1A2
Crohns Disease (2012)	3.1	3	2	4.4	0.00	1.0e+00	MST1 RASIP1 SULT1A2
Fasting Glucose	3.7	1	1	2.2	0.00	1.0e+00	FNDC4
HDL Cholesterol	1.7	2	1	2.2	0.00	1.0e+00	MLXIPL RBM6
LDL Cholesterol	1.6	1	1	2.2	0.00	1.0e+00	RASIP1
Neuroticism (2016)	2.1	2	0	0.0	0.00	1.0e+00	C1QTNF4 TCF4
Primary Biliary Cirrhosis	1.8	1	0	0.0	0.00	1.0e+00	LRRC37A
Schizophrenia (2014)	1.4	3	1	2.2	0.00	1.0e+00	ACVR2B CDK2AP1 LRRC37A
Triglycerides	13.9	3	2	4.4	0.00	1.0e+00	C16orf93 FNDC4 MLXIPL
Ulcerative Colitis	1.8	1	1	2.2	0.00	1.0e+00	MST1
Blood Eosinophil Count	1.5	8	4	8.9	-0.27	5.2e-01	ADH1C C16orf93 CDK2AP1 DOC2A H2AFV LRRC37A MLXIPL RBM6
Blood Platelet Count	4.5	13	12	26.7	0.33	2.6e-01	ADH1B C1QTNF4 C4orf44 CBX5 CDK2AP1 DHX40 ECE2 FNDC4 H2AFV LRRC37A MLXIPL NYAP1 RASIP1
Blood Red Count	3.4	14	11	24.4	0.29	3.1e-01	C16orf93 CTC-498M16.2 DOC2A ECE2 FKBP1B FNDC4 H2AFV KLB LRRC37A MST1 POLA2 RBM6 RFC1 SULT1A2
Blood White Count	3.5	15	12	26.7	0.57	2.7e-02	C16orf93 C1QTNF4 C4orf44 CTC-498M16.2 DHX40 FKBP1B FNDC4 H2AFV LRRC37A MLXIPL NPC1 NYAP1 RBM6 TUBG2 UBXN2A
Heel T-Score	1.9	10	6	13.3	0.13	7.2e-01	C16orf93 CDK2AP1 LEAP2 LRRC37A MST1 NPC1 NYAP1 RBM6 STAG3L2 TUBG2
BMI	5.3	22	14	31.1	0.54	8.9e-03	ACVR2B ADH1C C16orf93 C1QTNF4 C4orf44 CADM2 CBX5 CTC-498M16.2 DOC2A ECE2 FNDC4 FOXP1 H2AFV MLXIPL MST1 NPC1 PDXDC2P RBM6 STAG3L2 SULT1A2 TMED6 TUBG2
Height	2.2	26	20	44.4	-0.16	4.2e-01	C16orf93 C1QTNF4 C4orf44 CDK2AP1 DOC2A ECE2 EFNB3 FKBP1B FNDC4 KLB LIAS LLGL1 LRRC37A MLXIPL NPC1 NYAP1 PDXDC2P RASIP1 RFC1 RP11-54O7.17 SAMHD1 SULT1A2 TCF4 TMED6 TXNL4B UBXN2A
Waist Hip Ratio (WHR)	2.9	8	7	15.6	0.34	4.0e-01	C4orf44 CDK2AP1 LEAP2 LLGL1 LRRC37A MLXIPL RASIP1 RFC1
Systolic Blood Pressure	2.1	6	3	6.7	0.06	9.0e-01	C1QTNF4 CADM2 DOC2A FNDC4 MST1 RASIP1
Smoking Status	2.6	3	2	4.4	0.00	1.0e+00	CADM2 FOXP1 RP11-89K21.1
Allergy or Eczema	1.3	3	2	4.4	0.00	1.0e+00	CDK2AP1 SULT1A2 TUBG2
Cardiovascular Disease	2.9	9	5	11.1	0.66	5.2e-02	C16orf93 C4orf44 FNDC4 MLXIPL NPC1 PDXDC2P POLA2 RASIP1 STAG3L2
Hypothyroidism (self reported)	1.1	1	1	2.2	0.00	1.0e+00	RASIP1
Respiratory disease	1.1	1	0	0.0	0.00	1.0e+00	RBM6
Type 2 Diabetes (T2D) (2018)	3.5	4	2	4.4	0.03	9.7e-01	C1QTNF4 FNDC4 HMG20A RBM6
Lung FEV1/FVC ratio	1.2	4	3	6.7	-0.28	7.2e-01	C16orf93 LLGL1 LRRC37A RASIP1
Lung FVC	2.5	8	7	15.6	-0.68	6.6e-02	ACVR2B ADH1B C16orf93 FOXP1 LEAP2 LRRC37A TCF4 UBXN2A
Neuroticism	2.9	5	4	8.9	0.45	4.4e-01	C1QTNF4 CADM2 CTC-498M16.2 LRRC37A TCF4
Chronotype (morning person)	1.8	2	1	2.2	0.00	1.0e+00	CBX5 TXNL4B
Hair Pigment	0.2	4	2	4.4	0.42	5.8e-01	CDK2AP1 FNDC4 LRRC37A MLXIPL
Tanning	0.5	4	2	4.4	0.06	9.4e-01	C1QTNF4 CADM2 FNDC4 MLXIPL
Hand grip strength (left)	3.4	9	5	11.1	-0.59	9.6e-02	ACVR2B C16orf93 C1QTNF4 CADM2 DOC2A FOXP1 LRRC37A NYAP1 TCF4
Number of treatments/medications taken	2.6	3	1	2.2	0.00	1.0e+00	FNDC4 RBM6 STAG3L2
Average weekly spirits intake	2.0	1	0	0.0	0.00	1.0e+00	RASIP1
Sensitivity / hurt feelings	2.1	1	1	2.2	0.00	1.0e+00	LRRC37A
Hearing difficulty/problems: Yes	1.4	1	0	0.0	0.00	1.0e+00	C4orf44
Relative age of first facial hair	3.3	3	2	4.4	0.00	1.0e+00	FNDC4 LRRC37A NPC1
Systolic blood pressure, automated reading	1.9	3	0	0.0	0.00	1.0e+00	C1QTNF4 RASIP1 TSNARE1
Medication: Metformin	2.8	2	2	4.4	0.00	1.0e+00	C1QTNF4 FNDC4
Diabetes (father)	2.0	1	0	0.0	0.00	1.0e+00	FNDC4
Impedance of leg (right)	3.3	14	10	22.2	-0.29	3.2e-01	ACVR2B C16orf93 CADM2 CBX5 DHX40 DOC2A ECE2 FNDC4 LLGL1 MLXIPL PDXDC2P RBM6 STAG3L2 SULT1A2
Leg fat-free mass (left)	4.4	18	12	26.7	0.15	5.4e-01	ACVR2B C16orf93 CADM2 CBX5 CDK2AP1 CTC-498M16.2 DOC2A ECE2 EFNB3 FKBP1B FNDC4 MLXIPL NPC1 RBM6 SAMHD1 SULT1A2 TUBG2 UBXN2A
Trunk fat percentage	4.3	11	6	13.3	0.88	3.7e-04	C16orf93 C1QTNF4 C4orf44 FOXP1 HMG20A LRRC37A NPC1 PDXDC2P RBM6 SULT1A2 TUBG2
Hand grip strength (right)	3.0	7	2	4.4	-0.28	5.4e-01	ACVR2B C1QTNF4 CADM2 DOC2A KLB LRRC37A NYAP1
Fed-up feelings	2.4	4	1	2.2	0.99	1.2e-02	CDK2AP1 LRRC37A MST1 RBM6
Relative age voice broke	2.8	1	1	2.2	0.00	1.0e+00	LRRC37A
Taking other prescription medications	2.6	2	1	2.2	0.00	1.0e+00	RBM6 STAG3L2
Age when periods started (menarche)	2.5	4	1	2.2	-0.65	3.5e-01	C1QTNF4 FKBP1B PDXDC2P STAG3L2
Heel bone mineral density (BMD) T-score, automated (left)	1.5	1	1	2.2	0.00	1.0e+00	RBM6
Qualifications: CSEs or equivalent	2.4	1	0	0.0	0.00	1.0e+00	LRRC37A
High blood pressure	1.8	4	0	0.0	-0.23	7.7e-01	C16orf93 C1QTNF4 RASIP1 STAG3L2
Hayfever, allergic rhinitis or eczema	1.3	2	0	0.0	0.00	1.0e+00	CDK2AP1 TUBG2
Sitting height	3.2	12	9	20.0	-0.79	2.1e-03	C1QTNF4 CDK2AP1 DOC2A FKBP1B FNDC4 LRRC37A MLXIPL RASIP1 RP11-54O7.17 SAMHD1 TMED6 UBXN2A
Body mass index (BMI)	5.5	21	13	28.9	0.64	1.8e-03	ADH1C C16orf93 C1QTNF4 C4orf44 CADM2 CBX5 CTC-498M16.2 DOC2A ECE2 FNDC4 FOXP1 H2AFV HMG20A MST1 NPC1 PDXDC2P RBM6 STAG3L2 SULT1A2 TMED6 TUBG2
Impedance of leg (left)	3.2	14	10	22.2	-0.17	5.6e-01	ACVR2B C16orf93 CADM2 CDK2AP1 DOC2A ECE2 FNDC4 LLGL1 LRRC37A MLXIPL PDXDC2P RBM6 STAG3L2 SULT1A2
Leg predicted mass (left)	4.4	18	12	26.7	0.16	5.4e-01	ACVR2B C16orf93 CADM2 CBX5 CDK2AP1 CTC-498M16.2 DOC2A ECE2 EFNB3 FKBP1B FNDC4 MLXIPL NPC1 RBM6 SAMHD1 SULT1A2 TUBG2 UBXN2A
Trunk fat mass	4.6	13	9	20.0	0.90	2.8e-05	C16orf93 C1QTNF4 CADM2 CTC-498M16.2 DOC2A ECE2 FOXP1 HMG20A NPC1 PDXDC2P RBM6 SULT1A2 TUBG2
Waist circumference	5.5	16	11	24.4	0.75	8.5e-04	ADH1C C16orf93 C1QTNF4 C4orf44 CADM2 CBX5 CTC-498M16.2 DOC2A ECE2 HMG20A NPC1 PDXDC2P RBM6 STAG3L2 SULT1A2 TUBG2
Number of incorrect matches in round	1.8	2	0	0.0	0.00	1.0e+00	C16orf93 DOC2A
Past tobacco smoking	3.0	3	2	4.4	0.00	1.0e+00	CADM2 NPC1 RP11-89K21.1
Alcohol usually taken with meals	2.2	1	1	2.2	0.00	1.0e+00	FOXP1
Nervous feelings	3.0	4	1	2.2	0.21	7.9e-01	C16orf93 CADM2 CTC-498M16.2 LRRC37A
Frequency of tenseness / restlessness in last 2 weeks	2.6	2	1	2.2	0.00	1.0e+00	C16orf93 LRRC37A
Hair/balding pattern: Pattern 2	1.9	1	1	2.2	0.00	1.0e+00	LRRC37A
Forced vital capacity (FVC)	2.5	5	4	8.9	-0.98	2.5e-03	C1QTNF4 FOXP1 LRRC37A TMED6 UBXN2A
Heel bone mineral density (BMD) T-score, automated (right)	1.4	1	1	2.2	0.00	1.0e+00	RBM6
Ever unenthusiastic/disinterested for a whole week	1.6	1	0	0.0	0.00	1.0e+00	LRRC37A
Qualifications: None of the above	3.5	7	4	8.9	0.97	3.8e-04	C4orf44 CDK2AP1 CTC-498M16.2 FOXP1 RBM6 SULT1A2 TSNARE1
Mouth/teeth dental problems	1.8	1	0	0.0	0.00	1.0e+00	RASIP1
Allergy	1.1	1	1	2.2	0.00	1.0e+00	CDK2AP1
Diabetes (self-reported)	2.9	2	2	4.4	0.00	1.0e+00	FNDC4 RBM6
Medication: Simvastatin	2.2	2	1	2.2	0.00	1.0e+00	FNDC4 RASIP1
Fluid intelligence score	3.4	4	3	6.7	-0.97	2.6e-02	CDK2AP1 FOXP1 RBM6 SULT1A2
Illnesses of siblings	2.3	1	0	0.0	0.00	1.0e+00	C4orf44
Neuroticism score	2.8	3	3	6.7	0.00	1.0e+00	C1QTNF4 LRRC37A TCF4
Weight	5.2	18	11	24.4	0.48	4.6e-02	C16orf93 C1QTNF4 CADM2 CBX5 CDK2AP1 CTC-498M16.2 DOC2A ECE2 FNDC4 HMG20A MLXIPL NPC1 PDXDC2P RBM6 SAMHD1 STAG3L2 SULT1A2 TUBG2
Impedance of arm (right)	4.1	13	7	15.6	-0.17	5.9e-01	ACVR2B C16orf93 C4orf44 CADM2 CBX5 CTC-498M16.2 DOC2A ECE2 FNDC4 LRRC37A MLXIPL RBM6 STAG3L2
Arm fat percentage (right)	4.9	14	9	20.0	0.96	7.0e-08	C16orf93 C1QTNF4 C4orf44 CTC-498M16.2 DOC2A ECE2 FOXP1 HMG20A NPC1 PDXDC2P RBM6 STAG3L2 SULT1A2 TUBG2
Trunk fat-free mass	4.4	18	15	33.3	-0.08	7.6e-01	ACVR2B C16orf93 CADM2 CBX5 CDK2AP1 CTC-498M16.2 DOC2A ECE2 EFNB3 FKBP1B FNDC4 MLXIPL NPC1 RASIP1 RBM6 SAMHD1 SULT1A2 UBXN2A
Hip circumference	4.8	18	13	28.9	0.56	1.6e-02	C16orf93 C1QTNF4 CADM2 CBX5 CDK2AP1 CTC-498M16.2 DOC2A ECE2 FNDC4 HMG20A MLXIPL NPC1 PDXDC2P POLA2 RASIP1 RBM6 STAG3L2 SULT1A2
Time employed in main current job	1.5	1	0	0.0	0.00	1.0e+00	LRRC37A
Alcohol intake versus 10 years previously	6.8	8	4	8.9	0.96	1.5e-04	CBX5 FNDC4 KLB LEAP2 RASIP1 RBM6 RFC1 RP11-54O7.17
Father's age at death	2.1	1	0	0.0	0.00	1.0e+00	CDK2AP1
Worrier / anxious feelings	2.9	4	2	4.4	0.51	4.9e-01	C16orf93 CADM2 LRRC37A TCF4
Frequency of tiredness / lethargy in last 2 weeks	2.1	2	1	2.2	0.00	1.0e+00	C4orf44 POLA2
Hair/balding pattern: Pattern 3	2.5	1	1	2.2	0.00	1.0e+00	LRRC37A
Number of live births	1.8	2	0	0.0	0.00	1.0e+00	CADM2 LRRC37A
Forced expiratory volume in 1-second (FEV1)	2.5	5	3	6.7	-0.97	5.9e-03	C16orf93 FOXP1 LRRC37A TMED6 UBXN2A
Pulse rate	1.5	1	1	2.2	0.00	1.0e+00	FNDC4
Qualifications: A levels/AS levels or equivalent	3.6	4	3	6.7	-0.92	8.3e-02	CDK2AP1 MST1 RBM6 SULT1A2
Mouth/teeth dental problems: Dentures	2.6	4	1	2.2	0.48	5.2e-01	C4orf44 DHX40 RASIP1 RBM6
Medication: Cholesterol lowering	2.8	3	1	2.2	0.00	1.0e+00	C4orf44 FNDC4 RASIP1
Forced expiratory volume in 1-second (FEV1), Best measure	2.5	7	3	6.7	-0.98	1.3e-04	C16orf93 C1QTNF4 FOXP1 LEAP2 LRRC37A TMED6 UBXN2A
Impedance of arm (left)	4.2	11	9	20.0	-0.13	7.1e-01	ACVR2B CADM2 CBX5 CTC-498M16.2 DOC2A ECE2 FNDC4 LRRC37A MLXIPL RBM6 STAG3L2
Arm fat mass (right)	5.4	17	11	24.4	0.61	9.2e-03	ADH1C C16orf93 C1QTNF4 C4orf44 CADM2 CTC-498M16.2 DOC2A ECE2 FNDC4 FOXP1 HMG20A NPC1 PDXDC2P RBM6 STAG3L2 SULT1A2 TUBG2
Trunk predicted mass	4.4	19	15	33.3	-0.01	9.7e-01	ACVR2B C16orf93 CADM2 CBX5 CDK2AP1 CTC-498M16.2 DOC2A ECE2 EFNB3 FKBP1B FNDC4 KLB MLXIPL NPC1 RASIP1 RBM6 SAMHD1 SULT1A2 UBXN2A
Standing height	2.2	18	10	22.2	-0.19	4.6e-01	C1QTNF4 C4orf44 CDK2AP1 DOC2A FKBP1B FNDC4 KLB LLGL1 LRRC37A NPC1 PDXDC2P RASIP1 RFC1 RP11-54O7.17 SAMHD1 SULT1A2 TMED6 UBXN2A
Breastfed as a baby	1.5	1	0	0.0	0.00	1.0e+00	CDK2AP1
Tense / 'highly strung'	1.8	2	0	0.0	0.00	1.0e+00	C16orf93 CADM2
Seen doctor (GP) for nerves, anxiety, tension or depression	2.4	1	1	2.2	0.00	1.0e+00	TCF4
Hair/balding pattern: Pattern 4	3.5	2	1	2.2	0.00	1.0e+00	CBX5 LRRC37A
Birth weight of first child	1.8	1	0	0.0	0.00	1.0e+00	SULT1A2
Peak expiratory flow (PEF)	2.2	3	1	2.2	0.00	1.0e+00	LRRC37A RASIP1 UBXN2A
Ever highly irritable/argumentative for 2 days	1.9	1	0	0.0	0.00	1.0e+00	RBM6
Qualifications: O levels/GCSEs or equivalent	2.5	1	1	2.2	0.00	1.0e+00	CDK2AP1
Medication: Paracetamol	2.3	1	1	2.2	0.00	1.0e+00	LRRC37A
Headache pain in last month	2.3	1	1	2.2	0.00	1.0e+00	LRRC37A
Medication for cholesterol, blood pressure or diabetes	2.1	1	0	0.0	0.00	1.0e+00	FNDC4
Gout (self-reported)	4.2	3	2	4.4	0.00	1.0e+00	FNDC4 MLXIPL RFC1
Birth weight	1.7	2	0	0.0	0.00	1.0e+00	ACVR2B UBXN2A
Forced vital capacity (FVC), Best measure	2.5	5	5	11.1	-0.99	1.6e-03	C1QTNF4 FOXP1 LRRC37A TMED6 UBXN2A
Body fat percentage	4.7	12	7	15.6	0.96	4.1e-07	C16orf93 C1QTNF4 C4orf44 CTC-498M16.2 DOC2A FOXP1 HMG20A NPC1 PDXDC2P RBM6 SULT1A2 TUBG2
Leg fat percentage (right)	4.6	15	9	20.0	0.78	6.0e-04	ADH1C C16orf93 C1QTNF4 C4orf44 CADM2 CTC-498M16.2 FOXP1 H2AFV HMG20A MST1 NPC1 PDXDC2P RBM6 SULT1A2 TMED6
Arm fat-free mass (right)	4.9	17	16	35.6	0.03	9.1e-01	ACVR2B C16orf93 CADM2 CBX5 CDK2AP1 CTC-498M16.2 DOC2A ECE2 FKBP1B FNDC4 MLXIPL NPC1 RASIP1 RBM6 SAMHD1 SULT1A2 UBXN2A
Comparative body size at age 10	3.4	7	4	8.9	0.69	8.9e-02	C16orf93 C1QTNF4 CADM2 CTC-498M16.2 NPC1 RASIP1 SULT1A2
Wheeze or whistling in the chest in last year	2.1	1	1	2.2	0.00	1.0e+00	RBM6
Number of children fathered	2.7	1	1	2.2	0.00	1.0e+00	CADM2
Reason for reducing amount of alcohol drunk: Health precaution	2.9	2	0	0.0	0.00	1.0e+00	CTC-498M16.2 RFC1
Age at first live birth	2.4	1	1	2.2	0.00	1.0e+00	RBM6
Shortness of breath walking on level ground	2.0	1	0	0.0	0.00	1.0e+00	NPC1
Qualifications: College or University degree	4.5	14	9	20.0	-0.88	3.4e-05	C4orf44 CADM2 CBX5 CDK2AP1 CTC-498M16.2 FKBP1B FOXP1 LEAP2 LRRC37A MST1 NPC1 NYAP1 RBM6 SULT1A2
Medication for pain relief, constipation, heartburn	2.3	2	2	4.4	0.00	1.0e+00	CDK2AP1 LRRC37A
Medication: Allopurinol	3.7	3	2	4.4	0.00	1.0e+00	FNDC4 MLXIPL RFC1
Whole body fat mass	5.0	17	11	24.4	0.78	2.3e-04	ADH1C C16orf93 C1QTNF4 C4orf44 CADM2 CTC-498M16.2 DOC2A ECE2 FOXP1 HMG20A MST1 NPC1 PDXDC2P RBM6 STAG3L2 SULT1A2 TUBG2
Leg fat mass (right)	5.3	20	10	22.2	0.62	3.6e-03	ADH1C C16orf93 C1QTNF4 C4orf44 CADM2 CBX5 CTC-498M16.2 DOC2A ECE2 FNDC4 FOXP1 H2AFV HMG20A MST1 NPC1 PDXDC2P RBM6 STAG3L2 SULT1A2 TUBG2
Arm predicted mass (right)	4.9	17	16	35.6	0.03	9.0e-01	ACVR2B C16orf93 CADM2 CBX5 CDK2AP1 CTC-498M16.2 DOC2A ECE2 FKBP1B FNDC4 MLXIPL NPC1 RASIP1 RBM6 SAMHD1 SULT1A2 UBXN2A
Pulse rate, automated reading	3.1	8	4	8.9	0.72	4.6e-02	C16orf93 C4orf44 CTC-498M16.2 ECE2 FNDC4 MLXIPL MST1 RBM6
Comparative height size at age 10	3.0	12	11	24.4	-0.02	9.5e-01	CDK2AP1 DOC2A ECE2 FKBP1B FNDC4 LRRC37A NPC1 RASIP1 SAMHD1 SULT1A2 TCF4 UBXN2A
Number of full sisters	2.0	1	0	0.0	0.00	1.0e+00	CADM2
Suffer from 'nerves'	2.9	4	3	6.7	0.23	7.7e-01	C16orf93 C1QTNF4 CADM2 SULT1A2
Overall health rating	3.0	5	2	4.4	0.94	1.7e-02	C16orf93 FOXP1 MST1 NPC1 RBM6
Age at last live birth	2.1	1	1	2.2	0.00	1.0e+00	RBM6
Leg pain on walking	1.7	1	0	0.0	0.00	1.0e+00	RBM6
Qualifications: NVQ or HND or HNC or equivalent	2.1	1	0	0.0	0.00	1.0e+00	RBM6
Supplements: Vitamin C	1.7	1	0	0.0	0.00	1.0e+00	LRRC37A
Hypertension (Self-reported)	1.9	3	1	2.2	0.00	1.0e+00	C16orf93 RASIP1 STAG3L2
Smoking status: Previous	2.9	3	1	2.2	0.00	1.0e+00	CADM2 NPC1 RP11-89K21.1
Forced expiratory volume in 1-second (FEV1), predicted	1.5	1	0	0.0	0.00	1.0e+00	LLGL1
Whole body fat-free mass	4.5	17	16	35.6	0.01	9.8e-01	ACVR2B C16orf93 CADM2 CBX5 CDK2AP1 CTC-498M16.2 DOC2A ECE2 EFNB3 FKBP1B FNDC4 MLXIPL NPC1 RBM6 SAMHD1 SULT1A2 UBXN2A
Leg fat-free mass (right)	4.3	18	14	31.1	0.14	5.7e-01	ACVR2B C16orf93 CADM2 CBX5 CDK2AP1 CTC-498M16.2 DOC2A ECE2 EFNB3 FKBP1B FNDC4 MLXIPL NPC1 RBM6 SAMHD1 SULT1A2 TUBG2 UBXN2A
Arm fat percentage (left)	5.0	14	8	17.8	0.96	7.3e-08	C16orf93 C1QTNF4 C4orf44 CTC-498M16.2 DOC2A ECE2 FOXP1 HMG20A NPC1 PDXDC2P RBM6 STAG3L2 SULT1A2 TUBG2
Average weekly red wine intake	5.2	5	3	6.7	-0.98	4.4e-03	CDK2AP1 CTC-498M16.2 FOXP1 MGAM NPC1
Handedness (chirality/laterality): Left-handed	2.0	2	0	0.0	0.00	1.0e+00	LRRC37A SULT1A2
Mood swings	3.1	4	3	6.7	0.61	3.9e-01	C1QTNF4 LRRC37A RBM6 TCF4
Loneliness, isolation	1.8	2	1	2.2	0.00	1.0e+00	C1QTNF4 LRRC37A
Long-standing illness, disability or infirmity	2.2	1	0	0.0	0.00	1.0e+00	RBM6
Diabetes diagnosed by doctor	3.1	4	2	4.4	-0.96	3.8e-02	FNDC4 PDXDC2P RBM6 TUBG2
Friendships satisfaction	1.6	1	0	0.0	0.00	1.0e+00	NPC1
Qualifications: nursing, teaching	2.4	2	1	2.2	0.00	1.0e+00	CBX5 CDK2AP1
Mouth/teeth dental problems: Mouth ulcers	2.2	1	1	2.2	0.00	1.0e+00	LRRC37A
Medication for cholesterol	2.3	2	1	2.2	0.00	1.0e+00	FNDC4 RASIP1
Mineral and other dietary supplements	1.6	1	0	0.0	0.00	1.0e+00	CTC-498M16.2
Asthma (self-reported)	1.3	1	0	0.0	0.00	1.0e+00	TUBG2
Smoking status: Current	2.0	1	0	0.0	0.00	1.0e+00	RP11-89K21.1
Forced expiratory volume in 1-second (FEV1), predicted percentage	2.1	2	2	4.4	0.00	1.0e+00	C16orf93 LRRC37A
Whole body water mass	4.6	17	15	33.3	0.00	9.9e-01	ACVR2B C16orf93 CADM2 CBX5 CDK2AP1 CTC-498M16.2 DOC2A ECE2 EFNB3 FKBP1B FNDC4 MLXIPL NPC1 RBM6 SAMHD1 SULT1A2 UBXN2A
Leg predicted mass (right)	4.3	18	14	31.1	0.14	5.8e-01	ACVR2B C16orf93 CADM2 CBX5 CDK2AP1 CTC-498M16.2 DOC2A ECE2 EFNB3 FKBP1B FNDC4 MLXIPL NPC1 RBM6 SAMHD1 SULT1A2 TUBG2 UBXN2A
Arm fat mass (left)	5.4	17	11	24.4	0.61	9.3e-03	ADH1C C16orf93 C1QTNF4 C4orf44 CADM2 CTC-498M16.2 DOC2A ECE2 FNDC4 FOXP1 HMG20A NPC1 PDXDC2P RBM6 STAG3L2 SULT1A2 TUBG2
Number of self-reported non-cancer illnesses	2.3	3	1	2.2	0.00	1.0e+00	FNDC4 RASIP1 STAG3L2
Average weekly champagne plus white wine intake	3.5	2	0	0.0	0.00	1.0e+00	CBX5 LRRC37A
Miserableness	2.8	4	4	8.9	0.49	5.1e-01	C1QTNF4 LRRC37A RBM6 TCF4
Guilty feelings	2.3	3	1	2.2	0.00	1.0e+00	C1QTNF4 LRRC37A UBXN2A
High cholesterol (Self-reported)	4.3	3	2	4.4	0.00	1.0e+00	C4orf44 FNDC4 RASIP1
Medication: Paracetamol	2.4	1	1	2.2	0.00	1.0e+00	LRRC37A
Medication: Atorvastatin	2.7	2	1	2.2	0.00	1.0e+00	FNDC4 RASIP1
Ever smoked	2.9	4	2	4.4	-0.89	1.1e-01	CADM2 CDK2AP1 NPC1 RP11-89K21.1
Basal metabolic rate	4.7	18	15	33.3	0.09	7.1e-01	ACVR2B C16orf93 CADM2 CBX5 CDK2AP1 CTC-498M16.2 DOC2A ECE2 EFNB3 FKBP1B FNDC4 MLXIPL NPC1 RBM6 SAMHD1 SULT1A2 TUBG2 UBXN2A
Leg fat percentage (left)	4.8	15	9	20.0	0.78	5.3e-04	ADH1C C16orf93 C1QTNF4 C4orf44 CADM2 CTC-498M16.2 FOXP1 H2AFV HMG20A MST1 NPC1 PDXDC2P RBM6 SULT1A2 UBXN2A
Arm fat-free mass (left)	5.0	17	16	35.6	0.05	8.4e-01	ACVR2B C16orf93 CADM2 CBX5 CDK2AP1 CTC-498M16.2 DOC2A ECE2 FKBP1B FNDC4 MLXIPL NPC1 RASIP1 RBM6 SAMHD1 SULT1A2 UBXN2A
Average weekly beer plus cider intake	3.5	4	1	2.2	-0.99	1.4e-02	ADH1B ADH1C RFC1 RP11-89K21.1
Irritability	1.9	2	1	2.2	0.00	1.0e+00	LRRC37A TCF4
Risk taking	2.6	1	1	2.2	0.00	1.0e+00	CADM2
Ever had prostate specific antigen (PSA) test	1.4	1	0	0.0	0.00	1.0e+00	CTC-498M16.2
Diastolic blood pressure, automated reading	2.6	5	4	8.9	0.99	2.1e-03	C16orf93 CDK2AP1 MST1 RBM6 TSNARE1
Vascular/heart problems diagnosed by doctor	1.9	3	0	0.0	0.00	1.0e+00	C16orf93 RASIP1 STAG3L2
Cholesterol lowering medication	2.7	2	1	2.2	0.00	1.0e+00	FNDC4 RASIP1
Pain experienced in last month	2.1	1	0	0.0	0.00	1.0e+00	SAMHD1
Impedance of whole body	4.0	14	11	24.4	-0.19	5.2e-01	ACVR2B C16orf93 CADM2 CBX5 CTC-498M16.2 DOC2A ECE2 FNDC4 LLGL1 LRRC37A MLXIPL PDXDC2P RBM6 STAG3L2
Leg fat mass (left)	5.5	20	10	22.2	0.62	3.9e-03	ADH1C C16orf93 C1QTNF4 C4orf44 CADM2 CBX5 CTC-498M16.2 DOC2A ECE2 FNDC4 FOXP1 H2AFV HMG20A MST1 NPC1 PDXDC2P RBM6 STAG3L2 SULT1A2 TUBG2
Arm predicted mass (left)	5.0	17	16	35.6	0.05	8.4e-01	ACVR2B C16orf93 CADM2 CBX5 CDK2AP1 CTC-498M16.2 DOC2A ECE2 FKBP1B FNDC4 MLXIPL NPC1 RASIP1 RBM6 SAMHD1 SULT1A2 UBXN2A

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adipose Subcutaneous	28	0.80	2.4
GTEx	Adipose Visceral Omentum	22	1.08	2.6
GTEx	Adrenal Gland	12	0.82	2.3
GTEx	Artery Aorta	32	1.07	2.5
GTEx	Artery Coronary	19	1.61	2.8
GTEx	Artery Tibial	29	0.77	2.4
GTEx	Brain Caudate basal ganglia	7	0.76	2.4
GTEx	Brain Cerebellar Hemisphere	15	1.01	2.5
GTEx	Brain Cerebellum	17	0.86	2.5
GTEx	Brain Cortex	17	1.64	2.9
GTEx	Brain Frontal Cortex BA9	10	1.08	2.6
GTEx	Brain Hippocampus	5	0.95	2.6
GTEx	Brain Hypothalamus	6	1.02	2.6
GTEx	Brain Nucleus accumbens basal ganglia	11	1.27	2.6
GTEx	Brain Putamen basal ganglia	8	1.28	2.6
GTEx	Breast Mammary Tissue	18	0.91	2.7
GTEx	Breast Mammary Tissue (Male)	13	1.09	2.4
GTEx	Breast Mammary Tissue (Female)	18	1.09	2.6
GTEx	Cells EBV-transformed lymphocytes	13	0.91	2.5
GTEx	Cells Transformed fibroblasts	32	0.76	2.3
GTEx	Colon Sigmoid	13	0.89	2.5
GTEx	Colon Transverse	23	1.11	2.5
GTEx	Esophagus Gastroesophageal Junction	22	1.52	2.8
GTEx	Esophagus Mucosa	36	1.08	2.5
GTEx	Esophagus Muscularis	33	1.02	2.5
GTEx	Heart Atrial Appendage	13	0.82	2.4
GTEx	Heart Left Ventricle	20	1.31	2.7
GTEx	Liver	10	1.39	2.4
GTEx	Lung	32	1.11	2.6
GTEx	Muscle Skeletal	26	0.90	2.4
GTEx	Nerve Tibial	31	0.72	2.4
GTEx	Ovary	13	1.43	3.1
GTEx	Pancreas	13	0.80	2.5
GTEx	Pituitary	14	1.26	2.4
GTEx	Prostate	12	1.44	2.8
GTEx	Skin Not Sun Exposed Suprapubic	28	1.14	2.6
GTEx	Skin Sun Exposed Lower leg	35	0.96	2.5
GTEx	Small Intestine Terminal Ileum	9	1.95	2.9
GTEx	Spleen	15	1.06	2.6
GTEx	Stomach	18	1.24	2.7
GTEx	Testis	26	0.82	2.4
GTEx	Thyroid	30	0.75	2.3
GTEx	Uterus	11	1.94	2.7
GTEx	Vagina	12	1.89	3.1
GTEx	Whole Blood	20	1.00	2.3
METSIM	Adipose	23	0.50	2.1
NTR	Blood	11	0.46	2.0
ROSMAP	Brain Pre-frontal Cortex	40	0.91	2.3
YFS	Blood	17	0.37	2.0
CommonMind	Brain Pre-frontal Cortex	22	0.41	2.2
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	13	0.79	2.3
The Cancer Genome Atlas	Breast Invasive Carcinoma	26	0.59	2.2
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	13	1.19	2.3
The Cancer Genome Atlas	Colon Adenocarcinoma	18	0.87	2.3
The Cancer Genome Atlas	Esophageal Carcinoma	8	1.17	2.3
The Cancer Genome Atlas	Glioblastoma Multiforme	3	0.29	2.2
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	16	0.59	2.2
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	26	0.63	2.1
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	16	0.78	2.3
The Cancer Genome Atlas	Brain Lower Grade Glioma	29	0.67	2.2
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	12	1.08	2.4
The Cancer Genome Atlas	Lung Adenocarcinoma	17	0.58	2.1
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	14	0.56	2.2
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	9	0.57	2.2
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	10	0.60	2.0
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	4	0.30	2.1
The Cancer Genome Atlas	Prostate Adenocarcinoma	23	0.50	2.1
The Cancer Genome Atlas	Rectum Adenocarcinoma	6	0.87	2.2
The Cancer Genome Atlas	Soft Tissue Sarcoma	7	0.66	2.2
The Cancer Genome Atlas	Skin Cutaneous Melanoma	4	0.75	2.1
The Cancer Genome Atlas	Stomach Adenocarcinoma	11	0.65	2.2
The Cancer Genome Atlas	Testicular Germ Cell Tumors	5	0.39	2.1
The Cancer Genome Atlas	Thyroid Carcinoma	24	0.47	2.1
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	3	0.59	2.1